New Four-Target antibody tested for Tough-to-Treat blood cancer
NCT ID NCT05192486
Summary
This early-stage study is testing a new, experimental antibody drug called GNC-038 in adults whose diffuse large B-cell lymphoma (DLBCL) has come back or hasn't responded to standard treatments. The main goals are to find a safe dose and see how the body processes the drug. Researchers will also look for early signs that the treatment might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Hospital of Hebei University
Baoding, Hebei, China
-
Ruijin Hospital, Shanghai JiaoTong University School of Medicine
Shanghai, Shanghai Municipality, 200025, China
-
Shenzhen Second People's Hospital
Shenzhen, Guangdong, China
-
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China
Conditions
Explore the condition pages connected to this study.